HURA vs. CMPX, AQST, ITOS, ETON, VIGL, HUMA, CYRX, ATXS, CKPT, and ARCT
Should you be buying TuHURA Biosciences stock or one of its competitors? The main competitors of TuHURA Biosciences include Compass Therapeutics (CMPX), Aquestive Therapeutics (AQST), iTeos Therapeutics (ITOS), Eton Pharmaceuticals (ETON), Vigil Neuroscience (VIGL), Humacyte (HUMA), CryoPort (CYRX), Astria Therapeutics (ATXS), Checkpoint Therapeutics (CKPT), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry.
TuHURA Biosciences vs. Its Competitors
TuHURA Biosciences (NASDAQ:HURA) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.
0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by company insiders. Comparatively, 29.8% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
TuHURA Biosciences has higher earnings, but lower revenue than Compass Therapeutics.
In the previous week, Compass Therapeutics had 1 more articles in the media than TuHURA Biosciences. MarketBeat recorded 3 mentions for Compass Therapeutics and 2 mentions for TuHURA Biosciences. Compass Therapeutics' average media sentiment score of 1.18 beat TuHURA Biosciences' score of 0.94 indicating that Compass Therapeutics is being referred to more favorably in the news media.
TuHURA Biosciences has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.
TuHURA Biosciences presently has a consensus target price of $12.67, indicating a potential upside of 450.72%. Compass Therapeutics has a consensus target price of $12.67, indicating a potential upside of 325.06%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe TuHURA Biosciences is more favorable than Compass Therapeutics.
TuHURA Biosciences' return on equity of 291.69% beat Compass Therapeutics' return on equity.
Summary
Compass Therapeutics beats TuHURA Biosciences on 7 of the 13 factors compared between the two stocks.
Get TuHURA Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for HURA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TuHURA Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:HURA) was last updated on 7/16/2025 by MarketBeat.com Staff
